Switch theme
Sign up to access all valuation multiples
JD Health is the largest healthcare e-commerce platform in China in terms of revenue. The company offers pharmaceutical drugs and healthcare products on its platform, both as a marketplace that connects merchants to consumers and as a first-party, or 1P, direct retailer. It also offers online consultation from real life doctors and separately partners with offline pharmacies that can provide location-based 24/7 delivery as part of an omnichannel initiative to complement its core e-commerce business. Its closest competitors are Alibaba Health, Ping An Good Doctor, and Meituan for its e-commerce business. As of Dec. 31, 2024, the platform has over 200 million active annual users and over 70,000 merchants. JD Health is 67.49% owned by its parent company, JD.com.
2018
3.6K+
LTM Revenue $9.2B
LTM EBITDA $455M
$9.3B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
JD Health has a last 12-month revenue (LTM) of $9.2B and a last 12-month EBITDA of $455M.
In the most recent fiscal year, JD Health achieved revenue of $7.4B and an EBITDA of $641M.
JD Health expects next 12-month revenue of XXX and NTM EBITDA of XXX
See JD Health valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $9.2B | XXX | $7.4B | XXX | XXX | XXX |
| Gross Profit | $2.1B | XXX | $1.7B | XXX | XXX | XXX |
| Gross Margin | 23% | XXX | 23% | XXX | XXX | XXX |
| EBITDA | $455M | XXX | $641M | XXX | XXX | XXX |
| EBITDA Margin | 5% | XXX | 9% | XXX | XXX | XXX |
| EBIT | $258M | XXX | $189M | XXX | XXX | XXX |
| EBIT Margin | 3% | XXX | 3% | XXX | XXX | XXX |
| Net Profit | $578M | XXX | $531M | XXX | XXX | XXX |
| Net Margin | 6% | XXX | 7% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, JD Health's stock price is HKD 40 (or $5).
JD Health has current market cap of HKD 128B (or $16.4B), and EV of HKD 73.1B (or $9.3B).
See JD Health trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $9.3B | $16.4B | XXX | XXX | XXX | XXX | $0.17 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, JD Health has market cap of $16.4B and EV of $9.3B.
JD Health's trades at 1.3x EV/Revenue multiple, and 14.6x EV/EBITDA.
Equity research analysts estimate JD Health's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
JD Health has a P/E ratio of 30.8x.
See valuation multiples for JD Health and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $16.4B | XXX | $16.4B | XXX | XXX | XXX |
| EV (current) | $9.3B | XXX | $9.3B | XXX | XXX | XXX |
| EV/Revenue | 1.1x | XXX | 1.3x | XXX | XXX | XXX |
| EV/EBITDA | 22.3x | XXX | 14.6x | XXX | XXX | XXX |
| EV/EBIT | 39.3x | XXX | 49.4x | XXX | XXX | XXX |
| EV/Gross Profit | 4.7x | XXX | n/a | XXX | XXX | XXX |
| P/E | 30.8x | XXX | 30.9x | XXX | XXX | XXX |
| EV/FCF | 13.9x | XXX | 17.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialJD Health's last 12 month revenue growth is 15%
JD Health's revenue per employee in the last FY averaged $2.1M, while opex per employee averaged $0.4M for the same period.
JD Health's rule of 40 is 20% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
JD Health's rule of X is 42% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for JD Health and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 15% | XXX | 19% | XXX | XXX | XXX |
| EBITDA Margin | 5% | XXX | 9% | XXX | XXX | XXX |
| EBITDA Growth | 12% | XXX | 7% | XXX | XXX | XXX |
| Rule of 40 | 20% | XXX | 23% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 42% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $2.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 5% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 2% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 20% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| MedPlus India | XXX | XXX | XXX | XXX | XXX | XXX |
| SC Ropharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Pague Menos | XXX | XXX | XXX | XXX | XXX | XXX |
| Droga Raia | XXX | XXX | XXX | XXX | XXX | XXX |
| Redcare Pharmacy | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
JD Health acquired XXX companies to date.
Last acquisition by JD Health was XXXXXXXX, XXXXX XXXXX XXXXXX . JD Health acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was JD Health founded? | JD Health was founded in 2018. |
| Where is JD Health headquartered? | JD Health is headquartered in Hong Kong. |
| How many employees does JD Health have? | As of today, JD Health has 3.6K+ employees. |
| Who is the CEO of JD Health? | JD Health's CEO is Mr. Enlin Jin. |
| Is JD Health publicy listed? | Yes, JD Health is a public company listed on HKG. |
| What is the stock symbol of JD Health? | JD Health trades under 06618 ticker. |
| When did JD Health go public? | JD Health went public in 2020. |
| Who are competitors of JD Health? | Similar companies to JD Health include e.g. MedPlus India, SC Ropharma, Pague Menos, Droga Raia. |
| What is the current market cap of JD Health? | JD Health's current market cap is $16.4B |
| What is the current revenue of JD Health? | JD Health's last 12 months revenue is $9.2B. |
| What is the current revenue growth of JD Health? | JD Health revenue growth (NTM/LTM) is 15%. |
| What is the current EV/Revenue multiple of JD Health? | Current revenue multiple of JD Health is 1.1x. |
| Is JD Health profitable? | Yes, JD Health is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of JD Health? | JD Health's last 12 months EBITDA is $455M. |
| What is JD Health's EBITDA margin? | JD Health's last 12 months EBITDA margin is 5%. |
| What is the current EV/EBITDA multiple of JD Health? | Current EBITDA multiple of JD Health is 22.3x. |
| What is the current FCF of JD Health? | JD Health's last 12 months FCF is $728M. |
| What is JD Health's FCF margin? | JD Health's last 12 months FCF margin is 8%. |
| What is the current EV/FCF multiple of JD Health? | Current FCF multiple of JD Health is 13.9x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
